cPass™ SARS-CoV-2

Neutralization Antibody Detection Kit (CE)

Home » COVID-19 Detection | cPass™ SARS-CoV-2 Neutralization Antibody Detection Kit (CE)

cPass Neutralization Antibody Detection kit detects circulating neutralizing antibodies against SARS-CoV-2 that block the interaction between the receptor binding domain (RBD) of the viral spike glycoprotein with the ACE2 cell surface receptor. This kit would be instrumental in vaccine and therapeutic development as it is suitable for all antibody isotypes and can be used to determine neutralizing antibodies in animal models without modification. The kit will also help in current COVID-19 investigations of sero-prevalence, assessment of herd immunity, longevity of protective immunity, efficacy of different vaccine candidates as well as tracking infection in animals.

Global patent protection for the kit will be firmly implemented.
96 well ELISA format test with ACE2 protein attached to the plate and HRP labeled RBD is used for detection.
Can be used with serum and plasma samples.
The kit comes with positive and negative controls.
4 wells are typically used for the controls, so 92 wells can be used for samples.

Watch the cPass video to learn how it works

Placing An Order

cPass™ SARS-CoV-2 Neutralization Antibody Detection Kit

Authorization

Size

96 Test

Quantity

Get A Quote

Product Introduction

GenScript cPass™ SARS-CoV-2 Neutralization Antibody Detection Kit, also known as SARS-CoV-2 Surrogate Virus Neutralization Test (sVNT) Kit, is faster, easier, more scalable and automatable alternative to the traditional neutralizing antibody tests, such as virus neutralization test (VNT), pseudo-virus neutralization test (pVNT) and plaque reduction neutralization test (PRNT). The kit has the capability of measuring functional neutralizing antibodies (NAbs) within an hour instead of the days required by the traditional tests. cPass Neutralization Antibody detection kit does not require live biological materials or strict biosafety containment for testing (i.e. BSL3 containment). All aspects of the quality management system are certified to ISO 13485. GenScript has acquired CE mark (Europe) and HSA provisional approval (Singapore) and has been issued Emergency Use Authorization (EUA) by U.S. FDA.
Basic knowledge of SARS-CoV-2 surrogate virus neutralization test (sVNT)

TA new coronavirus, SARS-CoV-2, has recently emerged to cause a human pandemic. There is an urgent need for a robust serological test to detect neutralizing antibodies to SARS-CoV-2. Validated serologic assays are important for contact tracing, identifying the viral reservoir and epidemiological studies.

There are two types of antibody tests that aim for detecting COVID-19 infection with sufficient specificity and sensitivity. The first type is the virus neutralization test (VNT) which detects neutralizing antibodies (NAbs) in a patient's blood. VNT requires handling live SARS-CoV-2 in a specialized biosafety level 3 (BSL3) containment facility which is tedious and time consuming, taking 2-4 days to complete. Pseudovirus-based virus neutralization test (pVNT) is similar, but still requires the use of live viruses and cells although handled in a BSL2 laboratory.

All other assays, such as ELISA and lateral flow rapid tests, represent the second assay type which detect only binding antibodies, and not Nab.

Professor Lin-Fa Wang's lab at Duke-NUS Medical School established a Surrogate virus neutralization test (sVNT) which detects NAbs, but without the need to use any live virus or cells and can be completed in 1-2 hours in a BSL2 lab. Using purified receptor binding domain (RBD) protein from the viral spike (S) protein and the host cell receptor ACE2, the test is designed to mimic the virus-host interaction by direct protein-protein interaction in a test tube or an ELISA plate well. This highly specific interaction can then be neutralized, i.e., blocked by highly specific Nabs in patient or animal sera in the same manner as in a conventional VNT.

Performance

Table 1:The kit has been evaluated in China, Singapore, and USA. Here's the data summary.

		RT-PCR or Presumed Negative
		Positive (n=193)	Negative (n=480)
GenScript cPass™ SARS-CoV-2 Neutralization Antibody Detection Kit	Positive	181	3
	Negative	12	477
	Sensitivity	93.80%
	Specificity		99.40%

Table 2: Data grouped by days.

Days post symptom onset or serum collection vs PCR test (combined)	# PCR positive	GenScript cPass™ SARS-CoV-2 Neutralization Antibody Detection Kit
	# PCR positive	# Positive results	Sensitivity
≤ 7	27	20	74.10%
≥ 8	159	154	96.90%
Unknown	7	7	100.00%
Total	193	181	93.80%

Documents

Protocols

COAs

SDS

Dislaimer

Features

Species Independent

Isotype Independent

High Specificity

High Sensitivity

Safe & Scalable

Technology

Product Introduction

Dr. Linfa Wang, Ph.D., FTSE, is the director of the Program in Emerging Infectious Diseases at Duke-NUS Medical School in Singapore. His team at Duke-NUS, worked together with Diagnostics Development Hub and GenScript co-developed cPass™ SARS-CoV-2 Neutralization Antibody Detection Kit.